Hydrogel treatment targets tumours

Hydrogels of cancer drug taxol injected directly into tumours have been shown to be more effective at inhibiting tumour growth than intravenous taxol injections of four times the dosage.Taxol is used to treat many forms of cancer, including breast, lung…

Hydrogels of cancer drug taxol injected directly into tumours have been shown to be more effective at inhibiting tumour growth than intravenous taxol injections of four times the dosage.Taxol is used to treat many forms of cancer, including breast, lung and ovarian cancer. Its administration is typically every three weeks by intravenous injection and it can take several hours to achieve the required dose.Hydrogels have great potential to reduce the dosing frequency of chemotherapy. They can hold exceptionally high drug loadings that are released in a controlled and sustained manner. However, synthesising such hydrogels is complex, ultimately resulting in low yields.Zhimou Yang and fellow researchers at Nankai University in China have successfully simplified the synthesis of taxol hydrogels. Their hydrogel contains taxol conjugated to folic acid. The folic acid facilitates tumour targeting as many cancer cells have folic acid receptors so the hydrogels will sustainably release their taxol cargo through ester bond hydrolysis at the site of cancer cells.Yang says a solid phase peptide synthesis they have developed to make a precursor to the folic acid–taxol conjugates is the key to the improved synthetic strategy. The folic acid–taxol conjugates are prepared in just two steps, with yields of approximately 40% and do not require complicated purification steps. This is a vast improvement over their previous work where five steps were required and yields were less than 10%.‘The gel formulation not only allows for extended release of the drug but also facilitates delivery and retention within the tumour,‘ says Joel Collier, a synthetic biomaterials expert at the University of Chicago in the US. ‘Because of the excellent control over release kinetics for these types of materials, this strategy could be widely useful, even beyond cancer therapeutics,’ he adds.Vitaliy Khutoryanskiy, a reader in pharmaceutical materials at the University of Reading in the UK, finds the concept of making taxol-containing hydrogels interesting. However, he says that injection of a liquid taxol formulation that is converted to a gel in situ by elevated levels of glutathione in tumour cells could be more feasible for medicinal applications.Extending this approach to other drugs and in situ gel formation seem likely avenues for further exploration.

References1 C Yang et al, Org. Biomol. Chem., 2013, DOI: 10.1039/c3ob40969d2 H Wang et al, Chem. Commun., 2011, 47, 4439 (DOI: 10.1039/c1cc10506j)

Related Content

Taxol

6 July 2011 Podcast | Compounds

This week’s podcast is about Taxol

Bacteria factories for Taxol precursors

30 September 2010 News Archive

E. coli bacteria have been engineered to produce precursors of one of the most widely used cancer drugs

Most Read

Seeding removes barrier to curious cocrystal

20 August 2013 Research

The caffeine•benzoic acid cocrystal that has eluded scientists for 60 years has finally been crystallised

Ball lightning captured in the lab

21 August 2013 Research

Scientists hope that prolonging the lifetime of glowing orbs of plasma will help them understand this mysterious and rare nat…

Most Commented

Unconsidered chemistry could amplify global warming

25 August 2013 Research

Dimethyl sulfide links ocean acidification and climate change and could push up global temperatures by 0.5°C by 2100

Latvian scientists look for the exit as funding situation worsens

20 August 2013 News and Analysis

Austerity measures have seen research cash fall to half the levels of 2008 in the Baltic state